Entre viejas, tras del fuego, hilando sus ruecas: escritura y oralidad en Retrato de la Lozana andaluza

This article studies Retrato de la Lozana andaluza, by Francisco Delicado (1528-1530), in the context of the emergence of a national linguistic awareness in Spain, to be found in works, such as the prologue to the Gramatica Castellana (1492) by Antonio de Nebrija and the Dialogo de la Lengua (1533) by Juan de Valdes. This article highlights Delicado's own philosophy of language and its effect on his literature by analyzing both the peculiar formal structure of the Retrato and the oral and colloquial nature of its dialogues. Delicado's vision is nowhere more present than in the meta textual reflections of the implied author on the art of portraying. Consequently, in dialogue with Walter Benjamin and Bronislaw Malinowski on the conflictive nature of orality and writing, this article weighs the epistemological relevance of Retrato in regards to the limits of the written representation of orality.Este articulo aborda Retrato de la Lozana andaluza (entre 1528 y 1530) de Francisco Delicado en el contexto del surgimiento de una conciencia linguistica nacional en Espana a partir de obras tales como el prologo a la Gramatica Castellana (1492) de Antonio de Nebrija y el Dialogo de la Lengua (1533) de Juan Valdes. El articulo expone la filosofia de Delicado sobre la lengua, y las repercusiones de dicha filosofia en su vision literaria, considerando la peculiar estructura de Retrato, en particular el caracter oral y coloquial de sus dialogos. El articulo relaciona este caracter oral con la reflexion meta-textual del autor implicito sobre el arte de retratar. Consecuentemente, en dialogo con las reflexiones de pensadores contemporaneos, como Bronislaw Malinowski y Walter Benjamin, sobre la relacion conflictiva de dos universos linguisticos y culturales, el de la oralidad y el de la escritura, este articulo sopesa la relevancia epistemologica de Retrato en lo concerniente a los limites de la representacion escrituraria de la oralidad.http://link.galegroup.com.ezproxy.bu.edu/apps/doc/A536928498/AONE?u=mlin_b_bumml&sid=AONE&xid=b67739a0.%20Accessed%207%20Feb.%202019.http://link.galegroup.com.ezproxy.bu.edu/apps/doc/A536928498/AONE?u=mlin_b_bumml&sid=AONE&xid=b67739a0.%20Accessed%207%20Feb.%202019.http://link.galegroup.com.ezproxy.bu.edu/apps/doc/A536928498/AONE?u=mlin_b_bumml&sid=AONE&xid=b67739a0.%20Accessed%207%20Feb.%202019.Published versio

Guía para redacción de Estudios de Casos Gestión Administrativa y Documental del Sena para herramienta tecnológica

Este artículo presenta una guía para redacción de estudios de casos como resultado del proceso de desarrollo del proyecto “Desarrollo de una herramienta tecnologíca de simulación en procedimientos administrativos que fortalezca los procesos de enseñanza – aprendizaje del área de Gestión Administrativa y Documental del SENA–CEGAFE”, el documento se construyó con el fin de facilitar al escritor, en la transcripción de estudios de casos como técnica didáctica en el proceso enseñanza – aprendizaje. Esta guía es una herramienta pedagógica en la formación profesional integral bajo el modelo constructivista y de aprendizaje significativo. El documento inicia con un glosario de términos, seguido se plantea un método y diseño de plan de investigación para la redacción de casos, y finalmente se elabora un mapa para guiar la escritura. Se validó los contenidos temáticos incluidos en el documento con dos pedagogos; Constanza Hurtado Peña, especialista en Pedagogía de los derechos humanos evaluadora externa de revista científica en el área de humanidades con una experiencia de ocho años de asesora pedagoga del CEGAFE SENA y el doctor José Antonio Nieva Chavez pedagogo SENA regional valle. La información obtenida en el documento ofrece al redactor una orientación desde el inicio de la redacción del estudio de caso al final de su escrito

Guía para redacción de Estudios de Casos Gestión Administrativa y Documental del Sena para herramienta tecnológica

Este artículo presenta una guía para redacción de estudios de casos como resultado del proceso de desarrollo del proyecto “Desarrollo de una herramienta tecnologíca de simulación en procedimientos administrativos que fortalezca los procesos de enseñanza – aprendizaje del área de Gestión Administrativa y Documental del SENA–CEGAFE”, el documento se construyó con el fin de facilitar al escritor, en la transcripción de estudios de casos como técnica didáctica en el proceso enseñanza – aprendizaje. Esta guía es una herramienta pedagógica en la formación profesional integral bajo el modelo constructivista y de aprendizaje significativo. El documento inicia con un glosario de términos, seguido se plantea un método y diseño de plan de investigación para la redacción de casos, y finalmente se elabora un mapa para guiar la escritura. Se validó los contenidos temáticos incluidos en el documento con dos pedagogos; Constanza Hurtado Peña, especialista en Pedagogía de los derechos humanos evaluadora externa de revista científica en el área de humanidades con una experiencia de ocho años de asesora pedagoga del CEGAFE SENA y el doctor José Antonio Nieva Chavez pedagogo SENA regional valle. La información obtenida en el documento ofrece al redactor una orientación desde el inicio de la redacción del estudio de caso al final de su escrito

On the interpretation of changes in the subtropical oxygen minimum zone volume off Chile during two La Niña events (2001 and 2007)

Oxygen minimum zones (OMZs) are extended oceanic regions for which dissolved oxygen concentration is extremely low. They are suspected to be expanding in response to global warming. However, currently, the mechanisms by which OMZ varies in response to climate variability are still uncertain. Here, the variability of the subtropical OMZ off central Chile of a regional coupled physical–biogeochemical regional model simulation was analyzed for the period 2000–2008, noting that its fluctuations were significant despite the relatively weak amplitude of the El Niño/Southern Oscillation (ENSO). In particular, the interannual variability in the OMZ volume (OMZVOL, defined as the volume with dissolved oxygen concentration (DO) ≤ 45μM) was approximately 38% larger than that of the seasonal cycle, with maximum and minimum anomalies of OMZVOL taking place during two cold La Niña (LN) years (2001 and 2007). The model analyses further reveal that these anomalies resulted from a combined effect of changes in (1) the oxygen-poor waters poleward transport by the Peru–Chile undercurrent (PCUC), (2) the intensity of quasi-zonal jets influencing the transport of water to and from the OMZ, and (3) the zonal DO transport related to mesoscale eddy activity. Specifically, the interannual variability of the PCUC modulated primarily the DO contents of the OMZ core [(DO) ≤ 20μM] and secondarily the OMZVOL, while cross-shore DO transport by the zonal jets and the eddy fluxes played a major role in ventilating and shaping the offshore extent of the OMZ. When the OMZVOL was maximum (minimum), the PCUC transport was slightly increased (reduced), which was associated with a reduction (increase) in the ventilation of the OMZ through negative (positive) anomalies of zonal advection and DO eddy fluxes. Our results demonstrate that significant natural interannual variability in the subtropical OMZ off Chile originates from the interplay between oceanic equatorial teleconnection (PCUC transport) and local non-linear dynamics (the zonal jets and mesoscale eddies)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)